{# ── Billing problem banner: payment failed (past_due) or retries exhausted (unpaid). Pro access is gated off by is_pro until the card is fixed, so prompt the user to update billing. ── #}
NASDAQ: ROIV Roivant Sciences Ltd. 10-K

Roivant posts $770M litigation gain, discontinues batoclimab after Phase 3 failures

Filed May 20, 2026 · Period ending March 31, 2026 · Compared to 10-K May 29, 2025 · ~1 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade ROIV commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Feedback
View original filing on SEC.gov

Generated by AI · May 26, 2026 5:35 AM